Tonix Pharmaceuticals Holding Corp.
corporate_fare Company Profile
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 39 items for TNXP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for TNXP spans 8-K, 10-Q.
Recent high-impact activity:
- Tonix Sues Dr. Reddy's on TONMYA Patents, Triggering 30-Month FDA Approval Stay
- Tonix Q3: TONMYA Sales $15.0M, Net Loss $53.3M, Going-Concern Warning
- Tonix Q3: TONMYA Sales $15.0M, Net Loss Widens to $53.3M, Runway to Early Q3 2027
- Tonix Q3 TONMYA Sales Hit $15M, But Net Loss Widens to $53.3M
- Phase 3 Data Show TONMYA Beats Placebo on Pain and FIQR at Week 14
Financial Snapshot
Short Interest & Short Volume
4.14 days to coverFINRA reported short interest of 3,318,461 shares in TNXP as of the October 30, 2026 settlement, a 12.9% increase from the prior period — about 4.1 days to cover at its recent average daily volume. On November 19, 2026, 56.5% of TNXP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.